Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Iradimed (IRMD) over the last 13 years, with Q3 2025 value amounting to $29.8 million.

  • Iradimed's Non-Current Assets rose 4930.85% to $29.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $108.6 million, marking a year-over-year increase of 5820.67%. This contributed to the annual value of $23.1 million for FY2024, which is 4288.81% up from last year.
  • As of Q3 2025, Iradimed's Non-Current Assets stood at $29.8 million, which was up 4930.85% from $29.1 million recorded in Q2 2025.
  • Iradimed's 5-year Non-Current Assets high stood at $29.8 million for Q3 2025, and its period low was $6.6 million during Q4 2021.
  • For the 5-year period, Iradimed's Non-Current Assets averaged around $14.7 million, with its median value being $15.3 million (2023).
  • As far as peak fluctuations go, Iradimed's Non-Current Assets tumbled by 2056.83% in 2021, and later surged by 11220.84% in 2023.
  • Over the past 5 years, Iradimed's Non-Current Assets (Quarter) stood at $6.6 million in 2021, then rose by 20.91% to $8.0 million in 2022, then surged by 101.33% to $16.2 million in 2023, then soared by 42.89% to $23.1 million in 2024, then increased by 29.11% to $29.8 million in 2025.
  • Its Non-Current Assets stands at $29.8 million for Q3 2025, versus $29.1 million for Q2 2025 and $26.6 million for Q1 2025.